Protective Effects of Royal Jelly against Cyclophosphamide-Induced Liver Damage
PDF
Cite
Share
Request
Original Article
P: 384-390
2020

Protective Effects of Royal Jelly against Cyclophosphamide-Induced Liver Damage

Acta Haematol Oncol Turc 2020;53(3):384-390
1. Department Of Histology And Embryology, Adıyaman University Faculty Of Medicine, Adıyaman,turkey
2. Department Of Obstetrics And Gynecology, Harran University Faculty Of Veterinary Medicine, Şanlıurfa, Turkey
3. Department Of Obstetrics And Gynecology, Adıyaman University Faculty Of Medicine, Adıyaman, Turkey
4. Gerger Directorate Of Agriculture And Forestry, Adıyaman, Turkey
5.
No information available.
No information available
Received Date: 2020-01-06T14:24:17
Accepted Date: 2020-12-30T17:30:56
PDF
Cite
Share
Request

Abstract

INTRODUCTION

The aim of the present study to evaluate the protective effects of Royal Jelly on the changes caused by Cyclophosphamide (CP)- induced liver damage.

METHODS

32 Wistar albino rats were divided randomly into 4 groups: Control (0.5 cc saline was given orally for 16 days), Royal Jelly group (100 mg / kg Royal Jelly was given orally for 16 days) CP group (100 mg / kg intraperitoneal (singledose) CP was injected), CP+Royal Jelly group (100 mg / kg intraperitoneal CP was injected and also 100 mg / kg Royal Jelly was given orally for 16 days). After the experimental study was completed, liver tissues were removed from each animal and fixed in 10% formaldehyde. And then liver tissues were examined histopathologically.

RESULTS

The liver tissue of the Control with the Royal Jelly treated groups had normal histological structures. However, toxic effects were observed such as degeneration of hepatocytes, sinusoidal dilatation and inflammation in the cyclophosphamide applied group. In the CP with Royal Jelly applied groups, Royal Jelly restored the CP-induced structural alterations in the liver tissue by the way of its antioxidant.

DISCUSSION AND CONCLUSION

Royal Jelly may be a potential preventive natural product against the hepatic toxicity associated with CP therapy.